SEARL signs license agreement with Mabwell for biological medicines

MG News | July 12, 2023 at 03:09 PM GMT+05:00

Add Mettisglobal as a Trusted Source on Google

0:00

July 12, 2023 (MLN): The Searle Company Limited (PSX: SEARL) has entered into a License Agreement with Mabwell Pharmaceuticals, China, the latest company’s filing showed.

Under this agreement, the company will manufacture, register, and market the Denosumab Biosimilars drugs in Pakistan.

This partnership will benefit the patients in Pakistan by providing high quality affordable biological medicines.

“The company is committed to increasing its portfolio of products and business which will enhance the quality of its earnings and shareholders' value,” It reads.

Mabwell Pharmaceuticals is an innovative biopharmaceutical company.

Copyright Mettis Link News

Related News

Name	Price/Vol	%Chg/NChg
KSE100	171,021.20 228.53M	-0.42% -718.25
ALLSHR	103,836.39 572.65M	-0.41% -422.85
KSE30	50,951.99 89.47M	-0.52% -264.77
KMI30	240,633.87 93.99M	-0.31% -756.80
KMIALLSHR	66,572.75 300.61M	-0.28% -185.59
BKTi	48,673.23 31.18M	-0.70% -343.86
OGTi	33,702.25 6.35M	-0.61% -205.57

Symbol	Bid/Ask	High/Low

Name	Last	High/Low	Chg/%Chg
BITCOIN FUTURES	64,470.00	64,470.00 63,875.00	255.00 0.40%
BRENT CRUDE	98.70	101.19 95.13	-1.99 -1.98%
RICHARDS BAY COAL MONTHLY	105.75	0.00 0.00	-1.55 -1.44%
ROTTERDAM COAL MONTHLY	121.10	121.10 121.10	0.70 0.58%
USD RBD PALM OLEIN	1,175.00	1,175.00 1,175.00	0.00 0.00%
CRUDE OIL - WTI	90.47	92.83 87.68	-1.72 -1.87%
SUGAR #11 WORLD	14.76	14.79 14.54	0.07 0.48%